Trial · NCT02154347

Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

NCT02154347, Phase 4, Completed, Kissei Pharmaceutical Co., Ltd.; results first posted 2019-09-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus. Trials, record NCT02154347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02154347

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
NCT number: NCT02154347
Status: Completed
Phases: Phase 4
Enrollment: 178 participants, actual
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: KAD-1229, Placebo, Insulin
First posted: 2014-06-03
Last updated: 2019-09-06
Results first posted: 2019-09-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in HbA1c	16 weeks

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in HbA1c	16 weeks	full analysis set	% (value of HbA1c)	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in HbA1c	Placebo/KAD-1229		0.05	Standard Deviation 1.04	% (value of HbA1c)
Change From Baseline in HbA1c	KAD-1229/KAD-1229		-0.61	Standard Deviation 0.87	% (value of HbA1c)

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Double-blind Period	STARTED	Placebo/KAD-1229	60
Double-blind Period	STARTED	KAD-1229/KAD-1229	118
Double-blind Period	COMPLETED	Placebo/KAD-1229	57
Double-blind Period	COMPLETED	KAD-1229/KAD-1229	114
Double-blind Period	NOT COMPLETED	Placebo/KAD-1229	3
Double-blind Period	NOT COMPLETED	KAD-1229/KAD-1229	4
Open-label Period	STARTED	Placebo/KAD-1229	57
Open-label Period	STARTED	KAD-1229/KAD-1229	113
Open-label Period	COMPLETED	Placebo/KAD-1229	50
Open-label Period	COMPLETED	KAD-1229/KAD-1229	88

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events105

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Cold sweat	Skin and subcutaneous tissue disorders	Placebo/KAD-1229 (Data Through Week 16)	0	60
other	Cold sweat	Skin and subcutaneous tissue disorders	KAD-1229/KAD-1229 (Data Through Week 16)	2	118
other	Cold sweat	Skin and subcutaneous tissue disorders	KAD-1229 (Data Through Week 52)	9	175
other	Hunger	General disorders	Placebo/KAD-1229 (Data Through Week 16)	1	60
other	Hunger	General disorders	KAD-1229/KAD-1229 (Data Through Week 16)	2	118
other	Hunger	General disorders	KAD-1229 (Data Through Week 52)	9	175
other	Asthenia	General disorders	Placebo/KAD-1229 (Data Through Week 16)	2	60
other	Asthenia	General disorders	KAD-1229/KAD-1229 (Data Through Week 16)	2	118
other	Asthenia	General disorders	KAD-1229 (Data Through Week 52)	8	175
other	Dizziness	Nervous system disorders	Placebo/KAD-1229 (Data Through Week 16)	1	60

1 to 10 of 105Source ClinicalTrials.gov

See all 105 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo/KAD-1229 (Data Through Week 16)	0	60
Total, all-cause mortality	KAD-1229/KAD-1229 (Data Through Week 16)	0	118
Total, all-cause mortality	KAD-1229 (Data Through Week 52)	0	175
Total, other adverse events	Placebo/KAD-1229 (Data Through Week 16)	19	60
Total, other adverse events	KAD-1229/KAD-1229 (Data Through Week 16)	28	118
Total, other adverse events	KAD-1229 (Data Through Week 52)	98	175
Total, serious adverse events	Placebo/KAD-1229 (Data Through Week 16)	2	60
Total, serious adverse events	KAD-1229/KAD-1229 (Data Through Week 16)	4	118
Total, serious adverse events	KAD-1229 (Data Through Week 52)	18	175

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02154347

GET https://conductscience.org/api/trials/v1/NCT02154347/events?page=2

API reference For AI assistants